2011
Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study
Giannoccaro M, Donadio V, Gomis Pèrez C, Borsini W, Di Stasi V, Liguori R. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurological Sciences 2011, 32: 361-363. PMID: 21290160, DOI: 10.1007/s10072-010-0475-2.Peer-Reviewed Original ResearchConceptsSmall fiber neuropathySensory axonal neuropathySkin nerve fibersMajor side effectsNew chemotherapeutic agentsMeans of immunofluorescencePostural dizzinessAutonomic neuropathyBortezomib therapyAutonomic symptomsUrinary disturbanceMultiple myelomaAxonal neuropathyBortezomib treatmentNerve fibersSide effectsNeuropathyChemotherapeutic agentsImmunofluorescence studiesSmall fibersBortezomibTreatmentIleusDizzinessSyncope
2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases
2004
Hookworm infection: new developments and prospects for control
Bungiro R, Cappello M. Hookworm infection: new developments and prospects for control. Current Opinion In Infectious Diseases 2004, 17: 421-426. PMID: 15353961, DOI: 10.1097/00001432-200410000-00006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHookworm infectionHookworm diseaseEffective global controlPathological immune responsesMajor health burdenParasite virulence factorsNew chemotherapeutic agentsDevelopment of vaccinesHookworm anaemiaImmunoepidemiological studiesMass chemotherapyHealth burdenImmune responseMolecular pathogenesisGrowth delayChemotherapeutic agentsInfectionVaccineSocioeconomic statusDiseaseVirulence factorsGlobal healthBenzimidazole anthelminthicsPathogenesisAnthelminthic resistance
2000
Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer
Lilenbaum R, Herbst R. Vinorelbine and Gemcitabine Combinations in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2000, 2: 123-127. PMID: 14731322, DOI: 10.3816/clc.2000.n.024.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerLung cancerSmall cell lung cancerPoor performance statusTaxane-based regimensVinorelbine/gemcitabinePlatinum-based regimensSingle-agent activityTreatment of patientsOverall response rateNew chemotherapeutic agentsNonoverlapping toxicitiesGemcitabine combinationElderly patientsPerformance statusRandomized studyResponse rateWeekly scheduleChemotherapeutic agentsVinorelbineRegimensGemcitabinePatientsRegimen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply